• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多囊肾病患者根据肾功能的粪便微生物组分析:一项初步研究。

Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study.

机构信息

1 Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA.

2 Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

出版信息

Exp Biol Med (Maywood). 2019 Apr;244(6):505-513. doi: 10.1177/1535370218818175. Epub 2018 Dec 12.

DOI:10.1177/1535370218818175
PMID:30539656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6547006/
Abstract

The heterogeneity of the renal disease, therapeutic interventions, and the original cause of the renal failure, all directly affect the microbiota. We delineate in this report the direct effect of decreased renal function on the bacterial composition following stringent criteria to eliminate the possibilities of other confounding factors and dissect the direct effects of the uremic milieu. We analyzed the microbiome following three different approaches to further evaluate the effects of mild, moderate and advanced renal insufficiency on the microbiome. We also present here a detailed functional analysis of the projected altered pathways secondary to changes in the microbiome composition.

摘要

肾脏疾病的异质性、治疗干预以及肾衰竭的原始病因都直接影响着微生物组。我们根据严格的标准,排除了其他混杂因素的可能性,并剖析了尿毒症环境对细菌组成的直接影响,在本报告中阐述了肾功能下降对细菌组成的直接影响。我们采用三种不同的方法来分析微生物组,以进一步评估轻度、中度和重度肾功能不全对微生物组的影响。此外,我们还对微生物组组成变化导致的潜在改变途径进行了详细的功能分析。

相似文献

1
Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study.多囊肾病患者根据肾功能的粪便微生物组分析:一项初步研究。
Exp Biol Med (Maywood). 2019 Apr;244(6):505-513. doi: 10.1177/1535370218818175. Epub 2018 Dec 12.
2
Altered fecal microbial and metabolic profiles reveal potential mechanisms underlying anemia in patients with chronic renal failure.粪便微生物群和代谢谱的改变揭示了慢性肾衰竭患者贫血潜在的发病机制。
Microbiol Spectr. 2025 Aug 5;13(8):e0316624. doi: 10.1128/spectrum.03166-24. Epub 2025 Jun 17.
3
Evaluation of the Correlation between Gut Microbiota and Renal Function in Chronic Kidney Disease Patients.慢性肾脏病患者肠道微生物群与肾功能的相关性评估
J Microbiol Biotechnol. 2025 Jun 17;35:e2502039. doi: 10.4014/jmb.2502.02039.
4
BioImpedance Spectroscopy to maintain Renal Output: the BISTRO randomised controlled trial.生物电阻抗光谱法维持肾输出量:BISTRO随机对照试验
Health Technol Assess. 2025 Jul;29(32):1-23. doi: 10.3310/RHON2378.
5
Impact of Gut Microbiome Modulation on Uremic Toxin Reduction in Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.肠道微生物群调节对慢性肾脏病患者尿毒症毒素降低的影响:一项系统评价和网状Meta分析
Nutrients. 2025 Apr 3;17(7):1247. doi: 10.3390/nu17071247.
6
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.慢性肾脏病患者的合生菌、益生元和益生菌。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013631. doi: 10.1002/14651858.CD013631.pub2.
7
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.儿童癌症潜在肾毒性治疗后的早期和晚期肾脏不良反应。
Cochrane Database Syst Rev. 2013 Oct 8(10):CD008944. doi: 10.1002/14651858.CD008944.pub2.
8
Effects of Nut Intake on Gut Microbiome Composition and Gut Function in Adults: A Systematic Review and Meta-analysis.成人坚果摄入对肠道微生物群组成和肠道功能的影响:一项系统评价和荟萃分析
Adv Nutr. 2025 Jul;16(7):100465. doi: 10.1016/j.advnut.2025.100465. Epub 2025 Jun 13.
9
Alterations in the Gut Microbiome and Metabolisms in Pregnancies with Fetal Growth Restriction.胎儿生长受限妊娠中肠道微生物组和代谢物的改变。
Microbiol Spectr. 2023 Jun 15;11(3):e0007623. doi: 10.1128/spectrum.00076-23. Epub 2023 May 18.
10
The Impact of a 10-Month Synbiotic Intake on eGFR, Uremic Toxins, Oxidative Stress, and Inflammatory Markers in Non-Dialysis Chronic Kidney Disease Patients: A Prospective, Non-Randomized, Placebo-Controlled Study.为期10个月的合生元摄入对非透析慢性肾病患者估算肾小球滤过率、尿毒症毒素、氧化应激和炎症标志物的影响:一项前瞻性、非随机、安慰剂对照研究
Medicina (Kaunas). 2025 Jun 30;61(7):1199. doi: 10.3390/medicina61071199.

引用本文的文献

1
Differences in gut microbiome between autosomal dominant polycystic kidney disease with and without intracranial aneurysms.伴有和不伴有颅内动脉瘤的常染色体显性多囊肾病患者肠道微生物群的差异。
Sci Rep. 2025 Jul 7;15(1):24204. doi: 10.1038/s41598-025-08942-y.
2
Gut microbiota and kidney function in autosomal dominant polycystic kidney disease participants in Cameroon: a cross-sectional study.喀麦隆常染色体显性多囊肾病患者的肠道微生物群与肾功能:一项横断面研究。
BMC Nephrol. 2025 Jan 13;26(1):20. doi: 10.1186/s12882-025-03942-6.
3
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.触发警告:现代饮食、生活方式和环境如何引发常染色体显性遗传性多囊肾病的进展。
Nutrients. 2024 Sep 27;16(19):3281. doi: 10.3390/nu16193281.
4
The Influence of Non-Pharmacological and Pharmacological Interventions on the Course of Autosomal Dominant Polycystic Kidney Disease.非药物和药物干预对常染色体显性遗传性多囊肾病病程的影响。
Nutrients. 2024 Sep 23;16(18):3216. doi: 10.3390/nu16183216.
5
Ketogenic Interventions in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Review of Current Evidence.酮症干预治疗常染色体显性遗传多囊肾病:当前证据的综合评价。
Nutrients. 2024 Aug 13;16(16):2676. doi: 10.3390/nu16162676.
6
Potential Molecular Mechanisms of Alcohol Use Disorder with Non-Coding RNAs and Gut Microbiota for the Development of Superior Therapeutic Application.酒精使用障碍与非编码RNA和肠道微生物群在开发高级治疗应用方面的潜在分子机制
Genes (Basel). 2024 Mar 29;15(4):431. doi: 10.3390/genes15040431.
7
Dynamic gut microbiome-metabolome in cationic bovine serum albumin induced experimental immune-complex glomerulonephritis and effect of losartan and mycophenolate mofetil on microbiota modulation.阳离子牛血清白蛋白诱导的实验性免疫复合物性肾小球肾炎中的动态肠道微生物组-代谢组以及氯沙坦和霉酚酸酯对微生物群调节的作用
J Pharm Anal. 2024 Apr;14(4):100931. doi: 10.1016/j.jpha.2023.12.021. Epub 2023 Dec 30.
8
Integrated 16S rRNA sequencing and metabolomic analysis reveals the potential protective mechanism of Germacrone on diabetic nephropathy in mice.整合 16S rRNA 测序和代谢组学分析揭示了姜酮对糖尿病肾病小鼠的潜在保护机制。
Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):414-426. doi: 10.3724/abbs.2024021.
9
Inspiring Tactics with the Improvement of Mitophagy and Redox Balance for the Development of Innovative Treatment against Polycystic Kidney Disease.通过提高自噬和氧化还原平衡来激发策略,为多囊肾病的创新治疗开发提供新的思路。
Biomolecules. 2024 Feb 9;14(2):207. doi: 10.3390/biom14020207.
10
Gut Dysbiosis and Kidney Diseases.肠道菌群失调与肾脏疾病
Front Med (Lausanne). 2022 Mar 3;9:829349. doi: 10.3389/fmed.2022.829349. eCollection 2022.

本文引用的文献

1
The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus.2 型糖尿病频繁使用的降糖药物与肠道微生物群的关系。
J Diabetes Res. 2018 May 7;2018:1890978. doi: 10.1155/2018/1890978. eCollection 2018.
2
Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis.慢性肾脏病、尿毒症环境及其对肠道细菌微生物群落失调的影响。
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F487-F502. doi: 10.1152/ajprenal.00092.2018. Epub 2018 Apr 25.
3
Lupus: The microbiome angle.狼疮:微生物群视角。
Immunobiology. 2018 Jun-Jul;223(6-7):460-465. doi: 10.1016/j.imbio.2017.11.004. Epub 2017 Nov 16.
4
Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism.先天和适应性淋巴细胞依次塑造肠道微生物群和脂质代谢。
Nature. 2018 Feb 8;554(7691):255-259. doi: 10.1038/nature25437. Epub 2018 Jan 22.
5
Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases.微生物群衍生的短链脂肪酸通过组蛋白脱乙酰酶促进结肠中的组蛋白巴豆酰化。
Nat Commun. 2018 Jan 9;9(1):105. doi: 10.1038/s41467-017-02651-5.
6
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论:2017 年 KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)诊治临床实践指南更新。
Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.
7
Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial.晚期糖基化终产物饮食限制对腹膜透析患者肠道细菌微生物群的影响;一项随机开放标签对照试验。
PLoS One. 2017 Sep 20;12(9):e0184789. doi: 10.1371/journal.pone.0184789. eCollection 2017.
8
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.2017KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)指南更新执行摘要:有哪些变化,以及为什么这很重要。
Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006.
9
Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for Inflammation and Atherosclerosis?肠道微生物群中的短链脂肪酸是炎症和动脉粥样硬化的防御者吗?
J Atheroscler Thromb. 2017 Jul 1;24(7):660-672. doi: 10.5551/jat.RV17006. Epub 2017 May 27.
10
Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.肾功能受损和肠道微生物群落失调导致慢性肾脏病患者中三甲胺-N-氧化物水平升高。
Sci Rep. 2017 May 3;7(1):1445. doi: 10.1038/s41598-017-01387-y.